Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Common Equity (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Common Equity for 6 consecutive years, with $956.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 6.45% to $956.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $956.8 million through Dec 2025, down 6.45% year-over-year, with the annual reading at $956.8 million for FY2025, 6.45% down from the prior year.
  • Common Equity for Q4 2025 was $956.8 million at Janux Therapeutics, down from $976.6 million in the prior quarter.
  • The five-year high for Common Equity was $1.0 billion in Q4 2024, with the low at -$16.8 million in Q1 2021.
  • Average Common Equity over 5 years is $534.8 million, with a median of $371.5 million recorded in 2021.
  • The sharpest move saw Common Equity skyrocketed 3358.49% in 2021, then dropped 12.9% in 2023.
  • Over 5 years, Common Equity stood at $366.3 million in 2021, then decreased by 12.44% to $320.7 million in 2022, then grew by 7.36% to $344.3 million in 2023, then skyrocketed by 197.02% to $1.0 billion in 2024, then decreased by 6.45% to $956.8 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $956.8 million, $976.6 million, and $990.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.